In past few years, Clover has grown from a 20-person team to a global R&D powerhouse with a diverse global team of approximately 450 members, a robust pipeline enabled by our proprietary Trimer-Tag© technology, large in-house manufacturing capabilities, and strong partnerships with internationally renowned healthcare organizations.
2007
In 2007,Clover was founded as a research laboratory
2016
In Jul 2016,Clover executes agreement to establish and build 35,000 sqm commercial-scale cGMP biomanufacturing facility in Changxing, China and secures full-financing for the project (>RMB 350 million / >US$ 55 million)
2017
In Dec 2017,Clover completes Series A financing (RMB 62.8 million / US$ 9.5 million)
2018
In Jun 2018,First patient dosed with a product utilizing Trimer-Tag© technology (Phase 1 study of SCB-313 for treatment of cancer patients with malignant ascites)
2019
In Nov 2019,Clover completes Series B financing (RMB 304 million / US$ 43 million)
2020
In Jan 2020,Clover initiates development of COVID-19 vaccine candidate utilizing Trimer-Tag© technology
2020
In Feb-Mar 2020,Clover announces cross-border research collaborations with GSK and Dynavax utilizing their respective adjuvants for the development of COVID-19 vaccines
2020
In Apr 2020,Funding and collaboration with CEPI announced for Clover’s COVID-19 vaccine
2020
In Jun 2020,Clover completes Series B-2 financing (US$ 24 million / RMB 172 million) from Hillhouse Capital
2020
In Jun 2020,First participant dosed with Clover’s COVID-19 vaccine in Phase 1 clinical study
2020
In Jul 2020,CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate with an additional USD $66 million investment
2020
In Nov 2020,CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure (up to $328 million in grant funding)
2020
In Dec 2020,Clover announces positive Phase 1 data for its adjuvanted S-Trimer COVID-19 vaccine candidates
2021
In Feb 2021,Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing